ax-024
Small moleculeexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2014 (NCT02243683)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Nck adaptor protein 1INHIBITOR
NCK1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ax-024
- ax-024
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02546635 | Phase 1 | Aug 1, 2015 | Artax Biopharma Inc, Simbec-Orion |
| NCT02243683 | Phase 1 | Sep 1, 2014 | Artax Biopharma Inc, ORION Clinical Services, PCI Pharma Services, Simbec-Orion |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Artax Biopharma Inc | For profit | 2 | 2 | 1 | 2014 |
| Simbec-Orion | For profit | 2 | 0 | 1 | 2014 |
| ORION Clinical Services | For profit | 1 | 0 | 1 | 2014 |
| PCI Pharma Services | For profit | 1 | 0 | 1 | 2014 |
4 organizations
Page 1 / 1